A method for identifying an agonist exhibiting molecular or pharmacologic inhibition which is effective against the activity of at least one of iPLA2β and iPLA2γ which comprises culturing 3T3-L1 cells and transfecting them with negative control siRNA, siRNA directed against iPLA2β or siring directed against iPLA2γ prior to induction or during to differentiation or pharmacologic inhibition and observing for whether that down regulation of iPLA2β or iPLA2γ inhibits adipocyte differentiation.
展开▼